[Cusabio] CD19 Monoclonal Antibody- A Powerful Therapeutic Target For CAR-T
작성자
abbabio
작성일자
2019-08-08
조회수
344
If you are unable to see the message below, click here to view
CD19 is an IgSF surface glycoprotein of 95 kDa that is expressed from the earliest stages of B-cell development until plasma cell terminal differentiation, when its expression is lost. It is the most important surface marker of B cell, and is also a hot immune checkpoint in CAR T-cell therapy.
Currently, CD19 monoclonal antibodies have been explored for lymphoma therapy. Unconjugated mouse IgG2a anti-CD19 monoclonal antibody (mAb) was studied in six patients with progressive B cell lymphoma.
Now, CUSABIO develops a high quality CD19 Monoclonal Antibody for science research. This antibody has been validated in various applications, including ELISA, WB, IHC, IF and FC.
